Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, CNBC, Discovery, RT, and Viacom, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
There is a lot of hype about using AI to help design and discover new drugs, but we are starting to see results.
Researchers often spend billions of dollars and countless hours developing new drugs, only for the vast majority to fail long before they reach human trials. And in recent years some of those developers have started exploring ways to use Artificial Intelligence (AI) to help them discover new drugs, with one such AI designing 30,000 new drug combinations in just 21 days, some of which showed a lot of promise. Now though, in another development, one of those AI’s has managed to develop a promising new flu vaccine — all by itself.
The AI, called Smart Algorithms for Medical Discovery (SAM), is the work of researchers at Australia’s Flinders University.
The Flinders team started by feeding SAM information on chemical compounds known to activate the human immune system, as well as compounds known to have no effect on it, researcher Nikolai Petrovsky told Business Insider Australia.
Then they developed a computer program that could generate trillions of chemical compounds and let SAM decide which of those compounds might be promising candidates for new drugs.
The team then synthesized some of SAM’s top candidates and tested them on human blood cells in a lab. One of those candidates was a flu vaccine “turbocharger” that later proved incredibly effective in animals.
Clinical trials of the new vaccine in human patients have now kicked off all across the US, and if they go as hoped, we could be entering an era of fewer flus – and more AI developed drugs.